Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes - Top-Institutions - MDSpire

Evaluating Disability Progression in Multiple Sclerosis Through Patient-Reported Outcomes and Self-Administered Neuroperformance Metrics, Excluding Relapse Activity

  • By

  • Evy M. Reinders

  • Ariadna Masot-Llima

  • Susana Otero-Romero

  • René Carvajal

  • Álvaro Cobo-Calvo

  • Pere Carbonell-Mirabent

  • Jordina Beltran

  • Maria Jesús Arévalo

  • Helena Ariño

  • Georgina Arrambide

  • Cristina Auger

  • Luca Bollo

  • Joaquín Castilló

  • Manuel Comabella

  • Ingrid Galán

  • Alexis García-Sarreón

  • Andrew Goodman

  • Carrie M. Hersh

  • Delon La Puma

  • Le H. Hua

  • Luciana Midaglia

  • Neus Mongay-Ochoa

  • Ellen M. Mowry

  • Agustín Pappolla

  • Breogán Rodríguez-Acevedo

  • Jordi Río

  • Paula Tagliani

  • Ángela Vidal-Jordana

  • Andreu Vilaseca

  • Ana Zabalza

  • Deborah Pareto

  • Carlos Nos

  • Menno Schoonheim

  • Eva Strijbis

  • Jaume Sastre-Garriga

  • Madalina Tivarus

  • Tjalf Ziemssen

  • Àlex Rovira

  • Xavier Montalban

  • Mar Tintoré

  • Carmen Tur

  • July 6, 2026

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS)
    Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS)

    Cambridge, MA

    Key Differentiators

    • Multiple Sclerosis

  • #2

    Multiple Sclerosis Centre of Catalonia (Cemcat) at Vall d'Hebron University Hospital
    Multiple Sclerosis Centre of Catalonia (Cemcat) at Vall d'Hebron University Hospital

    Barcelona, Catalonia

    Key Differentiators

    • Multiple Sclerosis

  • #3

    Norwegian Registry for Spine Surgery (NORspine)
    Norwegian Registry for Spine Surgery (NORspine)

    Oslo, Oslo

    Key Differentiators

    • Spine Surgery

Original Source(s)

Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes

  • by Evy M. Reinders, Ariadna Masot-Llima, Susana Otero-Romero, René Carvajal, Álvaro Cobo-Calvo, Pere Carbonell-Mirabent, Jordina Beltran, Maria Jesús Arévalo, Helena Ariño, Georgina Arrambide, Cristina Auger, Luca Bollo, Joaquín Castilló, Manuel Comabella, Ingrid Galán, Alexis García-Sarreón, Andrew Goodman, Carrie M. Hersh, Delon La Puma, Le H. Hua, Luciana Midaglia, Neus Mongay-Ochoa, Ellen M. Mowry, Agustín Pappolla, Breogán Rodríguez-Acevedo, Jordi Río, Paula Tagliani, Ángela Vidal-Jordana, Andreu Vilaseca, Ana Zabalza, Deborah Pareto, Carlos Nos, Menno Schoonheim, Eva Strijbis, Jaume Sastre-Garriga, Madalina Tivarus, Tjalf Ziemssen, Àlex Rovira, Xavier Montalban, Mar Tintoré, Carmen Tur

  • July 6, 2026

Related Content

Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: Comparison of Treatment-Naïve Patients and Switchers in a Multicenter Cohort

Case Report: Multiple sclerosis and Neurofibromatosis type 1: a rare comorbidity

Multiple sclerosis as a biological and clinical continuum: from risk factors to the early stages of disease